Fisher Asset Management LLC Has $212,000 Stake in Quest Diagnostics Incorporated (NYSE:DGX)

Fisher Asset Management LLC trimmed its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 7.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,504 shares of the medical research company’s stock after selling 117 shares during the period. Fisher Asset Management LLC’s holdings in Quest Diagnostics were worth $212,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Yousif Capital Management LLC raised its stake in Quest Diagnostics by 5.3% in the 2nd quarter. Yousif Capital Management LLC now owns 26,926 shares of the medical research company’s stock valued at $3,785,000 after acquiring an additional 1,359 shares during the period. Integrated Wealth Concepts LLC boosted its holdings in shares of Quest Diagnostics by 220.5% during the 1st quarter. Integrated Wealth Concepts LLC now owns 13,959 shares of the medical research company’s stock worth $1,975,000 after buying an additional 9,604 shares during the period. LPL Financial LLC grew its stake in Quest Diagnostics by 4.4% in the 2nd quarter. LPL Financial LLC now owns 50,252 shares of the medical research company’s stock valued at $7,063,000 after buying an additional 2,103 shares during the last quarter. Truist Financial Corp raised its holdings in Quest Diagnostics by 2.2% in the 1st quarter. Truist Financial Corp now owns 23,459 shares of the medical research company’s stock valued at $3,319,000 after acquiring an additional 494 shares during the period. Finally, Vontobel Holding Ltd. lifted its position in Quest Diagnostics by 1.2% during the second quarter. Vontobel Holding Ltd. now owns 86,920 shares of the medical research company’s stock worth $12,217,000 after acquiring an additional 1,000 shares during the last quarter. 87.76% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics Price Performance

Shares of NYSE:DGX opened at $134.85 on Tuesday. The firm has a 50 day moving average of $126.98 and a 200-day moving average of $132.47. The stock has a market capitalization of $15.16 billion, a PE ratio of 20.25 and a beta of 0.92. The company has a current ratio of 1.12, a quick ratio of 1.01 and a debt-to-equity ratio of 0.61. Quest Diagnostics Incorporated has a 12 month low of $119.59 and a 12 month high of $158.34.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Tuesday, October 24th. The medical research company reported $2.22 EPS for the quarter, beating the consensus estimate of $2.19 by $0.03. The company had revenue of $2.30 billion during the quarter, compared to analysts’ expectations of $2.27 billion. Quest Diagnostics had a net margin of 8.21% and a return on equity of 15.80%. The business’s revenue for the quarter was down 7.7% compared to the same quarter last year. During the same period in the previous year, the company earned $2.36 EPS. On average, equities research analysts predict that Quest Diagnostics Incorporated will post 8.71 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Wednesday, January 17th will be paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 2.11%. The ex-dividend date is Tuesday, January 16th. Quest Diagnostics’s payout ratio is 42.64%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Morgan Stanley reaffirmed an “equal weight” rating and issued a $145.00 target price on shares of Quest Diagnostics in a research report on Thursday, August 3rd. Citigroup dropped their price target on Quest Diagnostics from $142.00 to $130.00 and set a “neutral” rating for the company in a report on Wednesday, October 25th. JPMorgan Chase & Co. lifted their price target on Quest Diagnostics from $148.00 to $149.00 and gave the stock a “neutral” rating in a report on Friday. Evercore ISI dropped their price target on Quest Diagnostics from $136.00 to $130.00 in a report on Wednesday, October 11th. Finally, Piper Sandler lifted their price target on Quest Diagnostics from $130.00 to $140.00 and gave the stock a “neutral” rating in a report on Monday, November 6th. Nine equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $146.09.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.